Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Stay informed and make data-driven decisions with our Ratings Table. Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan.

Stay up to date on Biogen analyst ratings. Delving into Biogen's Background Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer ...

Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Biogen (BIIB – Research Report) yesterday. The company’s shares closed yesterday at ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) saw some unusual options trading on Wednesday. Traders acquired 6,024 call ...